CEVEC Introduces CMO Services for the cGMP Manufacturing of CAP-based Clinical Materials

Cologne, Germany, September 23, 2014
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.
CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.
The CAP manufacturing joint venture with Lisbon based GenIbet operates state of the art cGMP manufacturing capabilities and allows for a one-stop offer for CEVEC customers in need of preclinical and clinical development of CAP Cell-derived materials.

CAP for Protein Production

Proteins

CAP and CAP-T Cells exhibit exceptional yields for complex proteins and antibodies. Authentic human-like post-translational modifications allow for higher specific activities and more cost-effective large scale productions of therapeutic molecules. A unique advantage of the transiently protein producing CAP-T Cells and the stably producing CAP Cells are identical and highest product qualities provided by an isogenic cellular background.

> READ MORE

CAP for Vaccine Production

Vaccines

CAP Cells exhibit key advantages in the field of vaccine development: adapted to animal component free suspension culture the human amniocyte derived cells propagate a very broad range of clinically relevant human viruses at high titers. Non-tumorous origin, development of the cell line under guidance of ethical advisory committees and a fully documented history from donor to Master Cell Bank position CAP as a versatile mammalian expression host.

> READ MORE

Clinical Material

cGMP

CEVEC is your contract manufacturer of choice for cGMP production in CAP Cells.
CAP-derived clinical material can be provided for phase I-II studies and we produce your desired protein, vaccine, virus or gene therapy vector at extraordinary pace and competitive pricing through our CAP CMO Joint Venture with Genibet in Lisbon/Portugal.

> READ MORE